Humatrope for short stature
Executive Summary
Lilly's growth hormone Humatrope (somatropin, rDNA origin) approved by FDA for idiopathic short stature July 25. Lilly will not conduct DTC advertising for Humatrope, will market the new indication only to pediatric endocrinologists and will distribute the product through controlled channels, as discussed during FDA's Endocrinologic & Metabolic Drugs Advisory Committee's June 10 review (1"The Pink Sheet" June 16, 2003, p. 28)...